Clinical Trial

SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39G with or without standard therapy in adult patients with advanced malignant solid tumors. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-18.
Trial Details
NCT Number NCT07665970
Lead Sponsor Sinocelltech Ltd.
Conditions Advanced Malignant Solid Tumors
Enrollment 112 participants
Start Date 2026-06-30
Primary Completion 2029-06-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-26